Venus Medtech targets European growth with senior appointment


Venus Medtech has appointed Shakeel Osman as senior vice president of sales Europe, responsible for the commercialisation of congenital heart devices. At present, the company’s transcatheter pulmonic valve replacement (TPVR) system—Venus P-Valve—is awaiting CE mark approval.

Prior to joining Venus Medtech, Shakeel Osman served as general manager UK & vice president sales Middle East Asia and Africa at Occlutech Medical Devices. As a 20-year veteran in the global marketing of medical devices, Osman has been heavily engaged in the European and Middle East markets, boasting extensive experience in marketing and distributor management in the cardiovascular field, Venus Medtech said in a press release.

Osman said: “It is a great honour to join Venus Medtech’s commercialisation team in Europe. As a leading company in structural heart disease, Venus Medtech possesses internationally competitive innovative pipelines. I’m excited to leverage my experience and work closely with the team to lay a solid foundation for the commercialisation of VenusP-Valve across Europe and contribute to the company’s global presence.”

In its press release, Venus Medtech claims that the VenusP-Valve is the only self-expanding TPVR system undergoing CE certification at the present time. It is expected to be Venus Medtech’s second medical device marketed in Europe following TriGUARD3 cerebral embolic protection device. In March 2021, VenusP-Valve received a special use authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Eric Zi, founder, executive director and general manager of Venus Medtech, welcomed Osman to the company. He said: “We are delighted to have another professional medical device marketing veteran joining Venus Medtech. The expertise and experience of Shakeel will be a tremendous addition to the commercialisation of VenusP-Valve in Europe, which is expected to give important weight to the clinical progress of future innovative devices in the market.”

Following the launch of TriGUARD3 in Europe in 2020, Venus Medtech has been committed to enhancing its international commercialisation endeavours to lay the foundations for global innovation and facilitate overseas clinical trials for more structural heart products. Furthermore, Venus Medtech appointed David Breant as vice president of sales Europe, responsible for the adult structural heart disease business, as well as direct sales in Germany, France and other markets; and Joyce Heo as director of sales, responsible for sales in emerging markets.


Please enter your comment!
Please enter your name here